Literature DB >> 10821985

Clinical pharmacology of oral cotinine.

S Zevin1, P Jacob, P Geppetti, N L Benowitz.   

Abstract

Cotinine is the major proximate metabolite of nicotine. The aims of our study were to assess the pharmacokinetics of oral cotinine comparing the use of saliva and plasma concentrations, and to characterize the subjective and cardiovascular effects of oral cotinine in nonsmokers. The clearance and half-life of cotinine measured using plasma or saliva concentrations were similar. There was no change in heart rate or blood pressure, and no differences in subjective response with cotinine compared to placebo. We conclude that administration of oral cotinine with measurement in saliva samples is easy, safe, and provides an accurate estimate of systemic clearance and half-life of cotinine.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10821985     DOI: 10.1016/s0376-8716(99)00135-0

Source DB:  PubMed          Journal:  Drug Alcohol Depend        ISSN: 0376-8716            Impact factor:   4.492


  10 in total

1.  Environmental and genetic determinants of tobacco use: methodology for a multidisciplinary, longitudinal family-based investigation.

Authors:  Gary E Swan; Karen Suchanek Hudmon; Lisa M Jack; Kymberli Hemberger; Dorit Carmelli; Taline V Khroyan; Huijun Z Ring; Hyman Hops; Judy A Andrews; Elizabeth Tildesley; Dale McBride; Neal Benowitz; Chris Webster; Kirk C Wilhelmsen; Heidi S Feiler; Barbara Koenig; Lorraine Caron; Judy Illes; Li S-C Cheng
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2003-10       Impact factor: 4.254

2.  Population pharmacokinetics of nicotine and its metabolites I. Model development.

Authors:  Micha Levi; Delia A Dempsey; Neal L Benowitz; Lewis B Sheiner
Journal:  J Pharmacokinet Pharmacodyn       Date:  2007-01-06       Impact factor: 2.745

3.  Assessment of nicotine dependence among adolescent and young adult smokers: a comparison of measures.

Authors:  Matthew J Carpenter; Nathaniel L Baker; Kevin M Gray; Himanshu P Upadhyaya
Journal:  Addict Behav       Date:  2010-06-22       Impact factor: 3.913

Review 4.  Substance misuse in patients with schizophrenia: epidemiology and management.

Authors:  David J Kavanagh; John McGrath; John B Saunders; Glenys Dore; Dianne Clark
Journal:  Drugs       Date:  2002       Impact factor: 9.546

5.  Chronic psychosocial stressors and salivary biomarkers in emerging adults.

Authors:  Andrew W Bergen; Aditi Mallick; Denise Nishita; Xin Wei; Martha Michel; Aaron Wacholder; Sean P David; Gary E Swan; Mark W Reid; Anne Simons; Judy A Andrews
Journal:  Psychoneuroendocrinology       Date:  2011-12-14       Impact factor: 4.905

6.  Genome-wide linkage of cotinine pharmacokinetics suggests candidate regions on chromosomes 9 and 11.

Authors:  Yungang He; Andrew W Bergen; Hyman Hops; Judy A Andrews; Elizabeth Tildesley; Christina N Lessov-Schlaggar; Cris Webster; Neal Benowitz; Gary E Swan
Journal:  Am J Med Genet B Neuropsychiatr Genet       Date:  2009-06-05       Impact factor: 3.568

Review 7.  Cotinine: A Therapy for Memory Extinction in Post-traumatic Stress Disorder.

Authors:  Cristhian Mendoza; George E Barreto; Alexandre Iarkov; Vadim V Tarasov; Gjumrakch Aliev; Valentina Echeverria
Journal:  Mol Neurobiol       Date:  2018-01-15       Impact factor: 5.590

8.  Urine nicotine metabolite concentrations in relation to plasma cotinine during low-level nicotine exposure.

Authors:  Neal L Benowitz; Katherine M Dains; Delia Dempsey; Brenda Herrera; Lisa Yu; Peyton Jacob
Journal:  Nicotine Tob Res       Date:  2009-06-12       Impact factor: 4.244

Review 9.  Cotinine: Pharmacologically Active Metabolite of Nicotine and Neural Mechanisms for Its Actions.

Authors:  Xiaoying Tan; Kent Vrana; Zheng-Ming Ding
Journal:  Front Behav Neurosci       Date:  2021-10-21       Impact factor: 3.617

10.  Effect of race and glucuronidation rates on the relationship between nicotine metabolite ratio and nicotine clearance.

Authors:  Evangelia Liakoni; Rachel F Tyndale; Peyton Jacob; Delia A Dempsey; Newton Addo; Neal L Benowitz
Journal:  Pharmacogenet Genomics       Date:  2021-07-01       Impact factor: 2.000

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.